Total Payments
$82,160
2024 Payments
$2,051
Companies
83
Transactions
1,116
Medicare Patients
12,360
Medicare Billing
$4.0M
Payment Breakdown by Category
Consulting$50,422 (61.4%)
Food & Beverage$20,527 (25.0%)
Other$8,850 (10.8%)
Travel$1,266 (1.5%)
Education$1,095 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $50,422 | 15 | 61.4% |
| Food and Beverage | $20,527 | 1,072 | 25.0% |
| Honoraria | $7,150 | 3 | 8.7% |
| Grant | $1,700 | 1 | 2.1% |
| Travel and Lodging | $1,266 | 3 | 1.5% |
| Education | $1,095 | 22 | 1.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Pharmacosmos Therapeutics Inc. | $39,355 | 10 | $0 (2023) |
| AMAG Pharmaceuticals, Inc. | $8,048 | 19 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $4,501 | 23 | $0 (2024) |
| WHITEHALL INTERNATIONAL INC | $4,000 | 2 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $3,404 | 37 | $0 (2024) |
| PFIZER INC. | $2,583 | 79 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $2,439 | 137 | $0 (2024) |
| Luitpold Pharmaceuticals Inc | $2,000 | 1 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $1,463 | 69 | $0 (2024) |
| Amgen Inc. | $1,340 | 75 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,051 | 95 | ABBVIE INC. ($258.72) |
| 2023 | $11,338 | 107 | Pharmacosmos Therapeutics Inc. ($9,095) |
| 2022 | $10,686 | 112 | Pharmacosmos Therapeutics Inc. ($8,462) |
| 2021 | $8,622 | 149 | Pharmacosmos Therapeutics Inc. ($5,798) |
| 2020 | $26,796 | 140 | Pharmacosmos Therapeutics Inc. ($16,000) |
| 2019 | $3,737 | 154 | AMAG Pharmaceuticals, Inc. ($1,027) |
| 2018 | $7,211 | 168 | Takeda Pharmaceuticals U.S.A., Inc. ($4,231) |
| 2017 | $11,719 | 191 | AMAG Pharmaceuticals, Inc. ($6,830) |
All Payment Transactions
1,116 individual payment records from CMS Open Payments — Page 1 of 45
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $13.86 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | Genentech USA, Inc. | Gazyva (Biological) | Food and Beverage | In-kind items and services | $29.72 | General |
| Category: BioOncology | ||||||
| 12/18/2024 | Myriad Genetic Laboratories, Inc. | MYRISK (Device) | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $28.74 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.71 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $17.83 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $5.13 | General |
| 11/27/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $13.43 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $24.20 | General |
| Category: BioOncology | ||||||
| 11/25/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $18.78 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.28 | General |
| Category: Oncology | ||||||
| 11/13/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $25.03 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $6.27 | General |
| 11/11/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $28.98 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $23.81 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/01/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $24.34 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | Incyte Corporation | MONJUVI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $23.89 | General |
| Category: Oncology | ||||||
| 10/29/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $19.73 | General |
| Category: Oncology | ||||||
| 10/22/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $2.56 | General |
| 10/17/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $17.63 | General |
| 10/10/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $22.62 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 2,896 | 142,947 | $3.4M | $980,069 |
| 2022 | 23 | 2,530 | 108,017 | $2.2M | $795,855 |
| 2021 | 30 | 3,466 | 329,692 | $2.5M | $864,935 |
| 2020 | 34 | 3,468 | 425,348 | $3.8M | $1.4M |
Total Patients
12,360
Total Services
1,006,004
Medicare Billing
$4.0M
Procedure Codes
119
All Medicare Procedures & Services
119 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 175 | 25,900 | $1.3M | $431,283 | 33.3% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 74 | 78,082 | $546,967 | $183,490 | 33.5% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 11 | 4,910 | $736,500 | $106,452 | 14.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 314 | 774 | $193,500 | $77,285 | 39.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 12 | 1,500 | $43,500 | $26,794 | 61.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 46 | 233 | $76,424 | $25,149 | 32.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 238 | 330 | $66,000 | $22,928 | 34.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 289 | 432 | $56,160 | $22,054 | 39.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 544 | 1,582 | $28,476 | $13,240 | 46.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 94 | 94 | $32,900 | $11,911 | 36.2% |
| J1750 | Injection, iron dextran, 50 mg | Office | 2023 | 33 | 784 | $21,952 | $10,554 | 48.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 475 | 1,348 | $35,048 | $10,201 | 29.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 11 | 149 | $15,198 | $9,133 | 60.1% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 26 | 21,420 | $64,260 | $8,309 | 12.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 57 | 224 | $15,680 | $5,244 | 33.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 115 | 359 | $14,360 | $4,041 | 28.1% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 60 | 317 | $66,887 | $2,108 | 3.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 60 | 152 | $6,840 | $1,885 | 27.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 13 | 31 | $4,805 | $1,715 | 35.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 19 | 19 | $6,650 | $1,583 | 23.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 15 | 52 | $3,744 | $1,227 | 32.8% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 11 | 29 | $2,958 | $764.38 | 25.8% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 17 | 920 | $46,000 | $749.39 | 1.6% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 14 | 20 | $1,940 | $637.40 | 32.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 11 | 11 | $1,100 | $486.80 | 44.3% |
About Dr. Michael Auerbach, M.D
Dr. Michael Auerbach, M.D is a Hematology & Oncology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336199942.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Auerbach, M.D has received a total of $82,160 in payments from pharmaceutical and medical device companies, with $2,051 received in 2024. These payments were reported across 1,116 transactions from 83 companies. The most common payment nature is "Consulting Fee" ($50,422).
As a Medicare-enrolled provider, Auerbach has provided services to 12,360 Medicare beneficiaries, totaling 1,006,004 services with total Medicare billing of $4.0M. Data is available for 4 years (2020–2023), covering 119 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Baltimore, MD
- Active Since 05/12/2006
- Last Updated 07/23/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1336199942
Products in Payments
- Monoferric (Drug) $21,798
- MONOFERRIC (Drug) $17,557
- FERAHEME (Drug) $8,048
- ICLUSIG (Drug) $4,151
- DAURISMO (Drug) $1,500
- IMBRUVICA (Drug) $803.88
- OPDIVO (Biological) $711.47
- KISQALI (Drug) $692.00
- XARELTO (Drug) $424.99
- IBRANCE (Drug) $419.22
- Revlimid (Drug) $411.20
- Ultomiris (Drug) $385.78
- KEYTRUDA (Biological) $384.17
- ADCETRIS (Biological) $372.85
- CALQUENCE (Drug) $350.21
- VENCLEXTA (Drug) $347.24
- TASIGNA (Drug) $346.13
- PROMACTA (Drug) $305.84
- EMPLICITI (Biological) $287.92
- Cabometyx (Drug) $283.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Baltimore
Miss. Ani Balmanoukian, M.d, M.D
Hematology & Oncology — Payments: $842,199
Hematology & Oncology $842,199
Dr. Benjamin Levy, Md, MD
Hematology & Oncology — Payments: $814,882
Hematology & Oncology $814,882
Dr. Patrick Forde, M.d, M.D
Hematology & Oncology — Payments: $253,665
Hematology & Oncology $253,665
Josephine Feliciano, M.d, M.D
Hematology & Oncology — Payments: $125,936
Hematology & Oncology $125,936
Djordje Atanackovic, M.d, M.D
Hematology & Oncology — Payments: $117,434
Hematology & Oncology $117,434
Huzefa Bahrain, D.o, D.O
Hematology & Oncology — Payments: $103,816
Hematology & Oncology $103,816